298 related articles for article (PubMed ID: 27197203)
1. Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth.
Pathania R; Ramachandran S; Mariappan G; Thakur P; Shi H; Choi JH; Manicassamy S; Kolhe R; Prasad PD; Sharma S; Lokeshwar BL; Ganapathy V; Thangaraju M
Cancer Res; 2016 Jun; 76(11):3224-35. PubMed ID: 27197203
[TBL] [Abstract][Full Text] [Related]
2. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
[TBL] [Abstract][Full Text] [Related]
3. Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation.
Peng Z; Zhou W; Zhang C; Liu H; Zhang Y
Med Sci Monit; 2018 Jan; 24():461-472. PubMed ID: 29363667
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma.
Chen DQ; Huang JY; Feng B; Pan BZ; De W; Wang R; Chen LB
PLoS One; 2014; 9(10):e109578. PubMed ID: 25279705
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
[TBL] [Abstract][Full Text] [Related]
6. Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.
Yang J; Fang Z; Wu J; Yin X; Fang Y; Zhao F; Zhu S; Li Y
Tumour Biol; 2016 Oct; 37(10):13871-13883. PubMed ID: 27485114
[TBL] [Abstract][Full Text] [Related]
7. miRNA-regulated delivery of lincRNA-p21 suppresses β-catenin signaling and tumorigenicity of colorectal cancer stem cells.
Wang J; Lei ZJ; Guo Y; Wang T; Qin ZY; Xiao HL; Fan LL; Chen DF; Bian XW; Liu J; Wang B
Oncotarget; 2015 Nov; 6(35):37852-70. PubMed ID: 26497997
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
Park SY; Kim MJ; Park SA; Kim JS; Min KN; Kim DK; Lim W; Nam JS; Sheen YY
Oncotarget; 2015 Nov; 6(35):37526-43. PubMed ID: 26462028
[TBL] [Abstract][Full Text] [Related]
9. The expression of stem cell protein Piwil2 and piR-932 in breast cancer.
Zhang H; Ren Y; Xu H; Pang D; Duan C; Liu C
Surg Oncol; 2013 Dec; 22(4):217-23. PubMed ID: 23992744
[TBL] [Abstract][Full Text] [Related]
10. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.
Hsu EC; Kulp SK; Huang HL; Tu HJ; Salunke SB; Sullivan NJ; Sun D; Wicha MS; Shapiro CL; Chen CS
Neoplasia; 2015 Jun; 17(6):497-508. PubMed ID: 26152358
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
Hii LW; Chung FF; Soo JS; Tan BS; Mai CW; Leong CO
Breast Cancer Res Treat; 2020 Feb; 179(3):615-629. PubMed ID: 31784862
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
[TBL] [Abstract][Full Text] [Related]
13. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
[TBL] [Abstract][Full Text] [Related]
14. Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Chao MW; Chu PC; Chuang HC; Shen FH; Chou CC; Hsu EC; Himmel LE; Huang HL; Tu HJ; Kulp SK; Teng CM; Chen CS
Oncotarget; 2016 Jan; 7(2):1796-807. PubMed ID: 26625202
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling.
Peng D; Tanikawa T; Li W; Zhao L; Vatan L; Szeliga W; Wan S; Wei S; Wang Y; Liu Y; Staroslawska E; Szubstarski F; Rolinski J; Grywalska E; Stanisławek A; Polkowski W; Kurylcio A; Kleer C; Chang AE; Wicha M; Sabel M; Zou W; Kryczek I
Cancer Res; 2016 Jun; 76(11):3156-65. PubMed ID: 27197152
[TBL] [Abstract][Full Text] [Related]
16. Ca2+/calmodulin-dependent protein kinase IIγ enhances stem-like traits and tumorigenicity of lung cancer cells.
Chai S; Xu X; Wang Y; Zhou Y; Zhang C; Yang Y; Yang Y; Xu H; Xu R; Wang K
Oncotarget; 2015 Jun; 6(18):16069-83. PubMed ID: 25965829
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta1 promotes the migration and invasion of sphere-forming stem-like cell subpopulations in esophageal cancer.
Yue D; Zhang Z; Li J; Chen X; Ping Y; Liu S; Shi X; Li L; Wang L; Huang L; Zhang B; Sun Y; Zhang Y
Exp Cell Res; 2015 Aug; 336(1):141-9. PubMed ID: 26096658
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
